Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an update.
Shanghai Fosun Pharmaceutical’s subsidiary, Shanghai Zhaohui Pharmaceutical Company Limited, has received approval from the National Medical Products Administration to begin Phase III clinical trials for a Ketoprofen Patch in China. This drug is intended for analgesic and anti-inflammatory uses, targeting conditions such as lower back pain, osteoarthritis, and rheumatoid arthritis. The approval marks a significant step in the company’s research and development efforts, potentially enhancing its market position and offering new treatment options for patients.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development and production of pharmaceutical products, with a market focus on both domestic and international markets.
Average Trading Volume: 5,426,976
Technical Sentiment Signal: Buy
Current Market Cap: HK$78.36B
For detailed information about 2196 stock, go to TipRanks’ Stock Analysis page.